既存治療を受けた神経内分泌腫瘍患者を対象としたカボザンチニブの研究 (CaboLife)
CaboLife:神経内分泌腫瘍の既往治療患者におけるカボザンチニブの実際の臨床現場での有効性と安全性に関する前向き非介入研究
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Ipsen Clinical Study Enquiries
- 電話番号:See e mail
- メール:clinical.trials@ipsen.com
研究場所
-
-
-
Graz、オーストリア
- 募集
- Medizinische Universitaet Graz
-
Linz、オーストリア
- まだ募集していません
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna、オーストリア
- 募集
- Medizinische Universität Wien
-
-
-
-
-
Aschaffenburg、ドイツ
- 募集
- MVZ am Klinikum Aschaffenburg
-
Berlin、ドイツ
- 募集
- Evangelische Lungenklinik Berlin
-
Berlin、ドイツ
- 募集
- DRK Kliniken Berlin
-
Berlin、ドイツ
- 募集
- Charité - Universitaetsmedizin Berlin
-
Bonn、ドイツ
- まだ募集していません
- Johanniter-Kliniken Bonn
-
Bremen、ドイツ
- 募集
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz、ドイツ
- まだ募集していません
- Klinikum Chemnitz
-
Cologne、ドイツ
- 募集
- pioh Studien und Mangement GbR
-
Cologne、ドイツ
- 募集
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden、ドイツ
- 募集
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden、ドイツ
- 募集
- Technische Univiersitaet (TU) Dresden
-
Erlangen、ドイツ
- 募集
- Universitaetsklinikum Erlangen
-
Essen、ドイツ
- 募集
- Universitaetsklinikum Essen
-
Frankfurt、ドイツ
- まだ募集していません
- Krankenhaus Nordwest
-
Frankfurt am Main、ドイツ
- まだ募集していません
- Uniklinikum Frankfurt
-
Freiburg im Breisgau、ドイツ
- 募集
- Universitaetsklinikum Freiburg
-
Giesen、ドイツ
- まだ募集していません
- Universitaetsklinikum Giessen-Marburg
-
Goettigen、ドイツ
- 募集
- Universitaetsmedizin Goettingen
-
Hamburg、ドイツ
- 募集
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg、ドイツ
- まだ募集していません
- Asklepios Kliniken Hamburg
-
Heidelberg、ドイツ
- まだ募集していません
- Universitaetsklinikum Heidelberg
-
Kiel、ドイツ
- まだ募集していません
- UKSH Kiel
-
Leer、ドイツ
- まだ募集していません
- Studienzentrum UnterEms
-
Leipzig、ドイツ
- まだ募集していません
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig、ドイツ
- まだ募集していません
- Universiteatsmedizin Leipzig
-
Ludwigsburg、ドイツ
- 募集
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck、ドイツ
- まだ募集していません
- UKSH Luebeck
-
Mainz、ドイツ
- まだ募集していません
- Universitaetsmedizin Mainz
-
Marburg、ドイツ
- 募集
- Philipps-Universitaet Marburg
-
Minden、ドイツ
- 募集
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim、ドイツ
- 募集
- MVZ Muelheim an der Ruhr GmbH
-
München、ドイツ
- まだ募集していません
- TUM Klinikum Muenchen
-
Münster、ドイツ
- まだ募集していません
- Universitaetsklinikum Muenster
-
Osnabrück、ドイツ
- まだ募集していません
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken、ドイツ
- まだ募集していません
- Universitaestklinikum Saarbruecken
-
Tübingen、ドイツ
- 募集
- Universitätsklinikum Tuebingen
-
Westerstede、ドイツ
- 募集
- Medizinische Studiengesellschaft Nord-West
-
Würzburg、ドイツ
- 募集
- Universitaetsklinikum Wuerzburg
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
説明
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease Control Rate (DCR)
時間枠:At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
時間枠:Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
時間枠:Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
時間枠:Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
時間枠:Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
時間枠:Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
時間枠:Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
時間枠:3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
時間枠:Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
時間枠:Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
時間枠:Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
時間枠:Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
時間枠:At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Ipsen Medical Director、Ipsen
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共有時間枠
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
IPD 共有アクセス基準
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。